The chronic pain market across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — was valued at approximately USD 12 billion in 2025 and is projected to grow at a CAGR of 5.1% through 2036. This steady expansion is being driven by the anticipated entry of advanced therapies, improved clinical management, and a growing understanding of the diverse mechanisms underlying persistent pain. As the broader pain management market matures, competition is shifting from a single, undifferentiated category toward indication-specific segments such as chronic back pain, osteoarthritis, migraine, fibromyalgia, and neuropathic pain.
Chronic Pain Overview
Chronic pain is defined as persistent or recurrent pain lasting beyond three months or beyond the expected period of tissue healing. It can stem from musculoskeletal disorders, neuropathic conditions, inflammatory diseases, cancer, and other chronic illnesses, and is frequently associated with sleep disturbances, emotional distress, and reduced quality of life — effects that are often compounded by aging and multiple comorbidities.
Chronic Pain Epidemiology
In 2025, the US recorded roughly 62 million prevalent cases of chronic pain and approximately 44 million diagnosed prevalent cases, underscoring substantial long-term demand within the chronic pain treatment market. Across EU4 and the UK, moderate-severity cases were most common (about 26 million), followed by severe (14 million) and mild (12 million) cases, with women representing a notably larger diagnosed population than men. In Japan, adults aged 65 and older carry the highest disease burden, and chronic back pain remains the leading contributor to the country’s overall chronic pain population — a trend expected to persist through 2036 as musculoskeletal conditions reshape the epidemiological landscape.
Chronic Pain Treatment Landscape
Current management combines pharmacological and non-pharmacological approaches, including non-opioid analgesics, NSAIDs, antidepressants, anticonvulsants, interventional procedures, physical therapy, and multidisciplinary rehabilitation. Despite this range of options, many patients continue to experience persistent symptoms, highlighting ongoing gaps within the pain management drugs market. Marketed products span multiple indications: EXILBY, NUCYNTA ER, BELBUCA, and XTAMPZA ER for chronic back pain; ZILRETTA and JOYCLU for osteoarthritis; EMGALITY, VYEPTI, AIMOVIG, AJOVY, BOTOX, and QULIPTA/AQUIPTA for migraine; TONMYA for fibromyalgia; and TARLIGE, QUTENZA, and HORIZANT for neuropathic pain — reflecting a broad and increasingly specialized chronic pain drugs market.
Chronic Pain Pipeline Analysis
The emerging pipeline adds further depth to the pain management therapeutics market, with late-stage assets including abobotulinumtoxinA (DYSPORT), XEOMIN, and rimegepant (NURTEC) for migraine; TLC599, Lorecivivint, MOTYS, and orforglipron for osteoarthritis; suzetrigine (JOURNAVX) for painful diabetic peripheral neuropathy; AXS-14 (esreboxetine) for fibromyalgia; and Vicatertide (SB-01), Rexlemestrocel-L, SP-102 (SEMDEXA), and VER-01 (EXILBY) for chronic lower back pain. Recent catalysts include Ipsen’s positive Phase III BEOND results for DYSPORT in migraine prevention, Eli Lilly’s Phase III TRIUMPH-1 data for retatrutide in knee osteoarthritis, and Novo Nordisk’s newly initiated Phase III trials for zenagamtide in obesity-related knee osteoarthritis — all pointing to a more mechanism-driven neuropathic pain market and adjacent pain categories going forward.
Chronic Pain Unmet Needs
Key unmet needs include the absence of predictive biomarkers for precision treatment, continued reliance on symptomatic analgesia, insufficient durable or long-acting therapies, inconsistent epidemiological data complicating pain management market size estimation, and fragmented multidisciplinary care that delays diagnosis and advanced treatment adoption.
Chronic Pain Market Outlook
By region, the US chronic pain market was valued at roughly USD 8 billion in 2025, while EU4 and the UK combined reached about USD 3 billion, with Germany contributing more than USD 900 million. Growth across the pain relief medication market is expected to continue as diagnosis rates improve, awareness increases, and novel targeted therapies enter the market. However, delayed diagnosis and prolonged trial-and-error prescribing — often centered on the broader painkiller market of NSAIDs, opioids, antidepressants, and anticonvulsants — may continue to slow adoption of newer, more targeted options.
Overall, the chronic pain space is transitioning from broad symptomatic management toward differentiated, mechanism-specific therapeutics, positioning the 2026–2036 forecast period as a pivotal decade for both patients and industry stakeholders.
Latest Reports Offered by Delveinsight
familial mediterranean fever market | food allergy market | functional electrical stimulation market | gastritis market | gaucher disease market | hemophilia b market | herpes simplex virus market | hiatal hernia market | holter monitor market | huntington’s disease market | hyperkalemia market | hyperuricemia market | idiopathic pulmonary fibrosis market | idiopathic thrombocytopenic purpura market | invasive candidiasis market | ischemic stroke market | jak inhibitor market | langerhans cell histiocytosis market | leukocyte adhesion deficiency market | metastatic urothelial carcinoma market | microscopy device market | monoclonal gammopathy of undetermined significance market | mrna based vaccines and therapeutics market | multiple myeloma market | neovascular age-related macular degeneration market | nephropathic cystinosis market | nerve repair and regeneration devices- market insights | nonmuscle invasive bladder cancer market | oncolytic virus cancer therapy market | ophthalmic laser devices market
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk